Hi-TIDe : HSC engineering

Gentner Lab

Our focus

Our objective is to apply advanced genetic engineering of hematopoietic stem cells in order to develop breakthrough cell therapies against cancer. Our strategies aim to create synergies between engineered haematopoiesis and adoptive T cell therapies. We boast a parallel clinical development that maximises the exchange between laboratory and bedside.


Our projects

  • Together with Pr Luigi Naldini in Milan (Italy), we have developed a hematopoietic stem cell (HSC)-based gene therapy to reprogram the tumor microenvironment (TME) by local interferon release from Tie2 expressing monocytes/macrophages. This treatment is currently being tested in a Phase I/IIa dose escalation study in glioblastoma multiforme patients (NCT03866109).
  • We are developing novel strategies to target transgene expression to tumor-infiltrating myeloid cells (TIMs), leveraging on curated single cell data and associated clinical outcomes from early clinical trials. HSC will be engineered with transcriptionally-regulated lentiviral vectors or by gene editing.
  • We will then exploit this TIM-specific delivery platform to deploy therapeutic payloads within the TME that synergize with adoptive T-cell therapies (T-cell ACT). Discovery of payloads that program synthetic anti-tumor cell network will be accomplished in collaboration with Hi-TIDe’s T cell systems engineering group and Tumor microenvironment & biomarker discovery group.
  • We are setting up a modular HSC transplantation platform in patients with advanced solid cancer, which can be combined with T-cell ACT, generating early human data that will further instruct the design of synthetic anti-tumor cell networks.
  • We are continuously innovating genetic HSC engineering. In the framework of a European consortium, we are developing purified HSC cultures, ex vivo expansion, gene/base editing and single cell HSC readouts.

Gentner Lab fig. 1.png


UNIL web teasers general.png


News @ Gentner Lab

Appointment of Bernhard Gentner to Hi-TIDe

Appointment of Bernhard Gentner to Hi-TIDe

Follow us:  


WEB medallions Linked 150 x100-1.png


bernhard_gentner-1800.jpg (Bernhard Gentner)

Bernhard GENTNER
Associate Professor
Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Attending Physician,Service of immuno-oncology, Lausanne University Hospital (CHUV)

Ludwig Lausanne RGB-crop461x374.jpg (Print)

Phone +41 79 556 9020


Ch. des Boveresses 155 - CH-1066 Epalinges
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer ResearchUniversité de LausanneCentre Hospitalier Universitaire Vaudois (CHUV)